Drug Profile
Buprenorphine implant - Molteni/Titan Pharmaceuticals
Alternative Names: Buprenorphine implant; Probuphine; SixmoLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Titan Pharmaceuticals
- Developer Accord Healthcare; Braeburn Pharmaceuticals; Knight Therapeutics; Titan Pharmaceuticals
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Opioid-related disorders
- No development reported Pain
Most Recent Events
- 13 Dec 2021 Preregistration for Opioid-related disorders (In adults) in United Kingdom (SC), prior to December 2021
- 13 Dec 2021 Registered for Opioid-related disorders (In adults) in United Kingdom (SC)
- 13 Dec 2021 The Scottish Medicines Consortium accepts Sixmo® (buprenorphine implant) for Opioid-related disorders (In adults) in the UK